FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2068444865> ?p ?o ?g. }

• W2068444865 endingPage "149" @default.
• W2068444865 startingPage "135" @default.
• W2068444865 abstract "Innovative approaches to care may be necessary to provide the most effective symptom management to hospice patients. One approach is prescribing newer pharmacotherapy options with the potential to improve symptom management in hospice. Such therapies are sometimes prescribed outside of Food and Drug Administration indications and are typically more costly than older agents usedfor the same symptoms. Another approach is the collaborative practice (CP) care model, whereby clinical pharmacists are given prescriptive authority according to evidence-based protocols and algorithms within boundaries approved by a physician. The agents typically included in CPprotocols are those with wide therapeutic indices and with substantial evidence to support their use. The purpose of this study was to examine both approaches to management ofpain, insomnia, and nausea, comparing symptom scores for those patients who received noncollaborative drug therapies (transdermal fentanyl, zolpidem, and ondansetron) to those who received agents under CP (oral sustained-release opioids, temazepam, andprochlorperazine). The object of the study was to investigate outcomes associated with newer drug therapy options as compared to older agents for the management of pain, insomnia, and nausea. A secondary goal is to compare symptom outcomes for patients receiving pharmaceutical care under CP and non-CP models. The study design was retrospective with a cohort. A total of 50 patients were randomly selected for each cohort of the pain and insomnia study arms. Only 45 patients prescribed oral ondansetron met inclusion criteriafor the nausea group; 45 patients prescribed prochlorperazine were randomly selected as the comparator group. Patients were compared on their degree of response to the prescribed therapy. Response was classified as complete, partial, no improvement from baseline, worsened, or unknown. A complete response was defined as the symptom score improving to a 0 of 10, regardless of the previous value documented. A partial response was defined as any improvement in score that did not result in a 0 of 10. No improvement from baseline reflected a lack of overall change in score throughout the series of data points collected. A worsened response was any score found to be higher than the score documented at the time of dispense. The unknown category reflects any set of scores that had an “NIA” documented at the time of medication dispense or when documented for both attempts subsequent to dispensing the medication. A complete response was present in 14 of 50 (24 percent) of the patients prescribed fentanyl as compared with 12 of 50 (28 percent) of those prescribed oral therapy (p = .82). Responses defined as partial, no improvement over baseline, worsened, and unknown were also comparable between the two cohorts. A complete response was seen in 26 patients prescribed temazepam (52 percent), whereas only 11 (22 percent) of patients initially prescribed zolpidem achieved the same response (p = .003 7). Both groups had a similar distribution of partial, no improvement over baseline, and worsened responses. For the nausea arm of the study, a difference was found in the number of complete responses, favoring prochlorperazine (22 of 45, 48.9 percent for prochlorperazine, 12 of 45, 26.7 percent for ondansetron, p =. 0504), as well as an increased number of worse responses seen with ondansetron patients (p = .0513); however, neither difference was statistically significant. Newer pharmacotherapy options for the management of pain, insomnia, and nausea were not found to be superior when compared to older agents prescribed under CR" @default.
• W2068444865 created "2016-06-24" @default.
• W2068444865 creator A5002938997 @default.
• W2068444865 creator A5034158096 @default.
• W2068444865 creator A5060496486 @default.
• W2068444865 creator A5083644177 @default.
• W2068444865 date "2006-03-01" @default.
• W2068444865 modified "2023-09-27" @default.
• W2068444865 title "Are newer, more expensive pharmacotherapy options associated with superior symptom control compared to less costly agents used in a collaborative practice setting?" @default.
• W2068444865 cites W161235706 @default.
• W2068444865 cites W1715752662 @default.
• W2068444865 cites W1866754648 @default.
• W2068444865 cites W1919669891 @default.
• W2068444865 cites W1934556984 @default.
• W2068444865 cites W1963561277 @default.
• W2068444865 cites W1987168851 @default.
• W2068444865 cites W1988733147 @default.
• W2068444865 cites W1990533630 @default.
• W2068444865 cites W1995877215 @default.
• W2068444865 cites W2004254017 @default.
• W2068444865 cites W2004643562 @default.
• W2068444865 cites W2012346691 @default.
• W2068444865 cites W2019040902 @default.
• W2068444865 cites W2022929615 @default.
• W2068444865 cites W2022974422 @default.
• W2068444865 cites W2023335302 @default.
• W2068444865 cites W2026245814 @default.
• W2068444865 cites W2032355978 @default.
• W2068444865 cites W2038403554 @default.
• W2068444865 cites W2038637825 @default.
• W2068444865 cites W2043033585 @default.
• W2068444865 cites W2051162794 @default.
• W2068444865 cites W2054860374 @default.
• W2068444865 cites W2055697278 @default.
• W2068444865 cites W2058537083 @default.
• W2068444865 cites W2059867560 @default.
• W2068444865 cites W2087424536 @default.
• W2068444865 cites W2088646788 @default.
• W2068444865 cites W2088894328 @default.
• W2068444865 cites W2090215632 @default.
• W2068444865 cites W2091683450 @default.
• W2068444865 cites W2093600933 @default.
• W2068444865 cites W2093800361 @default.
• W2068444865 cites W2099018421 @default.
• W2068444865 cites W2105231474 @default.
• W2068444865 cites W2107835464 @default.
• W2068444865 cites W2112502628 @default.
• W2068444865 cites W2113363852 @default.
• W2068444865 cites W2114044388 @default.
• W2068444865 cites W2116962240 @default.
• W2068444865 cites W2117688789 @default.
• W2068444865 cites W2117950925 @default.
• W2068444865 cites W2120649398 @default.
• W2068444865 cites W2125540170 @default.
• W2068444865 cites W2136584816 @default.
• W2068444865 cites W2140560577 @default.
• W2068444865 cites W2142973784 @default.
• W2068444865 cites W2147514996 @default.
• W2068444865 cites W2148000461 @default.
• W2068444865 cites W2148461943 @default.
• W2068444865 cites W2155937964 @default.
• W2068444865 cites W2165113702 @default.
• W2068444865 cites W2171787586 @default.
• W2068444865 cites W2177315914 @default.
• W2068444865 cites W2185259533 @default.
• W2068444865 cites W2346147946 @default.
• W2068444865 cites W2405408455 @default.
• W2068444865 doi "https://doi.org/10.1177/104990910602300211" @default.
• W2068444865 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16572752" @default.
• W2068444865 hasPublicationYear "2006" @default.
• W2068444865 type Work @default.
• W2068444865 sameAs 2068444865 @default.
• W2068444865 citedByCount "13" @default.
• W2068444865 countsByYear W20684448652012 @default.
• W2068444865 countsByYear W20684448652015 @default.
• W2068444865 countsByYear W20684448652017 @default.
• W2068444865 countsByYear W20684448652021 @default.
• W2068444865 countsByYear W20684448652022 @default.
• W2068444865 crossrefType "journal-article" @default.
• W2068444865 hasAuthorship W2068444865A5002938997 @default.
• W2068444865 hasAuthorship W2068444865A5034158096 @default.
• W2068444865 hasAuthorship W2068444865A5060496486 @default.
• W2068444865 hasAuthorship W2068444865A5083644177 @default.
• W2068444865 hasConcept C126322002 @default.
• W2068444865 hasConcept C170493617 @default.
• W2068444865 hasConcept C177713679 @default.
• W2068444865 hasConcept C2776029756 @default.
• W2068444865 hasConcept C2777170512 @default.
• W2068444865 hasConcept C2779706987 @default.
• W2068444865 hasConcept C2780580376 @default.
• W2068444865 hasConcept C2781063702 @default.
• W2068444865 hasConcept C2781324269 @default.
• W2068444865 hasConcept C42219234 @default.
• W2068444865 hasConcept C500440147 @default.
• W2068444865 hasConcept C71924100 @default.
• W2068444865 hasConceptScore W2068444865C126322002 @default.
• W2068444865 hasConceptScore W2068444865C170493617 @default.
• W2068444865 hasConceptScore W2068444865C177713679 @default.

• next